Last reviewed · How we verify
Wyeth-Lederle's Prevenar™
Prevenar is a conjugate vaccine that stimulates the body to produce antibodies against Streptococcus pneumoniae.
Prevenar is a conjugate vaccine that stimulates the body to produce antibodies against Streptococcus pneumoniae. Used for Prevention of invasive disease caused by Streptococcus pneumoniae in infants and young children.
At a glance
| Generic name | Wyeth-Lederle's Prevenar™ |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Conjugate vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious disease |
| Phase | Phase 3 |
Mechanism of action
Prevenar works by introducing inactivated Streptococcus pneumoniae polysaccharides conjugated to a carrier protein, which triggers an immune response and the production of antibodies that can recognize and neutralize the bacteria.
Approved indications
- Prevention of invasive disease caused by Streptococcus pneumoniae in infants and young children
Common side effects
- Injection site pain
- Fever
Key clinical trials
- Vaccination With GSK 1024850A in Children Primed With GSK 1024850A & Boosted With Pneumovax 23™ (PHASE3)
- Booster Vaccination Study With a Pneumococcal Vaccine in Children Primed With the Same Vaccine (PHASE3)
- Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Pneumococcal Vaccine in Healthy Children 15 m of Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Wyeth-Lederle's Prevenar™ CI brief — competitive landscape report
- Wyeth-Lederle's Prevenar™ updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI